1. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
   Maureen L. Drakes et al, 2020, Cancers CrossRef
2. Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review
   Yue Li et al, 2021, OncoTargets and Therapy CrossRef
3. Role of Human Epididymis Protein 4 in Tumour Angiogenesis
   Harshita Dubey et al, 2023, Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer CrossRef
4. PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
   null Boussios et al, 2019, Diagnostics CrossRef
5. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes
   Nicole E. James et al, 2020, Scientific Reports CrossRef
6. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
   Anna Pawłowska et al, 2021, International Journal of Molecular Sciences CrossRef
7. The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance
   Nele Loret et al, 2019, Cancers CrossRef
8. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
   Yang You et al, 2021, Frontiers in Molecular Biosciences CrossRef
9. Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1
   Jamaal L. James et al, 2019, Current Breast Cancer Reports CrossRef